The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option ...

Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

FDA approves Keytruda Qlex, a subcutaneous injection version of the widely used cancer therapy Keytruda Patients can now ...

While the test was conducted in NSCLC, the FDA approval includes existing solid tumor indications for Keytruda. Merck is ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

For the last two years, Keytruda has reigned as the world’s top-selling drug—a distinction under threat with key patent ...

Roche Holdings AG's RHHBY Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with ...

Vaccines, injectable antibiotics and any other injectable products should always be administered properly to minimize tissue residues, injection site lesions, adverse reactions and side effects.